Costs of extended immune check point inhibitors treatment in advanced/metastatic lung cancer: Bundling of costs proposal.

被引：0
|
作者：
Guirgis, Helmy M. [1 ]
机构：
[1] Canc Free Fdn, Dana Point, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21738
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Immune Check-Point Inhibitors and Standard Chemoradiotherapy in Definitive Head and Neck Cancer Treatment
    De Felice, Francesca
    Musio, Daniela
    Tombolini, Vincenzo
    JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (05):
  • [22] Characteristics, treatment patterns, and healthcare costs of advanced/metastatic biliary tract cancer patients in Japan
    Kim, Seok-Won
    Wang, Xin
    Chen, Chi-Chang
    Wada, Shingo
    Garside, Jamie
    Reese, Emily S.
    ANNALS OF ONCOLOGY, 2022, 33 : S496 - S496
  • [23] Impact of antibiotics and proton pump inhibitors on clinical outcomes of immune check point blockers in advanced non-small cell lung cancers and metastatic renal cell cancer.
    Kulkarni, Amit
    Kumar, Manoj
    Pease, Daniel Fellows
    Wang, Ying
    DeFor, Todd E.
    Patel, Manish
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [24] Immune Checkpoint Inhibitors and Additional Local Treatment in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer
    Atmaca, A.
    Wetzel, S.
    Van Kampen, M.
    Salam, S.
    Somuncuoglu, G.
    Veit, S.
    Jaeger, E.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S357 - S358
  • [25] The impact of PD-L1 on survival and value of the immune check point inhibitors in non-small-cell lung cancer; proposal, policies and perspective
    Guirgis, Helmy M.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [26] Venous thromboembolism in patients with advanced non-small cell lung cancer treated with immune check-point inhibitors: a retrospective cohort study
    Icht, O.
    Darzi, N.
    Landman, Y.
    Reinhorn, D.
    Shochat, T.
    Jacobi, O.
    Rotem, O.
    Dudnik, E.
    Spectre, G.
    Raanani, P.
    Zer, A.
    Leader, A.
    THROMBOSIS RESEARCH, 2021, 200 : S49 - S50
  • [27] Health care resource utilization and costs associated with advanced or metastatic nonsmall cell lung cancer in the United States
    Zhang, Xinke
    Beachler, Daniel C.
    Masters, Elizabeth
    Liu, Frank
    Yang, Mo
    Dinh, Jade
    Jamal-Allial, Aziza
    Kolitsopoulos, Francesca
    Lamy, Francois-Xavier
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2022, 28 (02): : 255 - 265
  • [28] ADVERSE EVENT (AE) MANAGEMENT COSTS ASSOCIATED WITH IMMUNE CHECKPOINT INHIBITORS (ICI) APPROVED FOR VARIOUS ADVANCED OR METASTATIC CANCERS IN THE US
    Ranjan, S.
    Gandhi, J.
    Mothe, R.
    Werwath, T.
    Ameen, R.
    Kk, M.
    Sagar, K.
    Potluri, R.
    VALUE IN HEALTH, 2024, 27 (12)
  • [29] The financial toxicity of non-small lung cancer treatment: The optimization of first and second-line therapy with immune check point inhibitors
    Giuliani, J.
    Bonetti, A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [30] The toxicity associated with combining immune check point inhibitors with tyrosine kinase inhibitors in patients with non-small cell lung cancer
    Kalra, Anjali
    Rashdan, Sawsan
    FRONTIERS IN ONCOLOGY, 2023, 13
12345